论文部分内容阅读
目的根据地方性氟骨症防治实际,探索治疗骨关节损害的药物。方法在改水或不改水中、重病区选择100例氟骨症病人作为治疗组给予芬必得,300mg,po,bid,设对照组给予苁蓉片,1.2g,po,bid。疗程4W。采用“新药(西药)临床研究指导原则”中所述方法与标准,结合地方性氟骨症症状体征表现进行观察与疗效评价。观察了2种药物的总体疗效,起效时间,副作用,患者对药物的耐受性。结果芬必得组有效率100%,苁蓉片对照组有效率86.49%(P<0.005)。芬必得组起效时间在1W内,副作用率20.00%;苁蓉片组起效时间在7～15d,副作用率35.14%。2组患者对药物的耐受性均较好。结论芬必得是治疗地方性氟骨症的有效药物,其效果明显优于苁蓉片。
Objective According to the actual prevention and treatment of endemic fluorosis, to explore the treatment of bone and joint damage drugs. Methods 100 cases of skeletal fluorosis patients were treated with Fenbid, 300mg, po, bid in control group. The control group was given Rongchang Tablets, 1.2g, po, bid. Treatment 4W. The methods and standards described in the Guiding Principles of Clinical Research of New Drugs (Western Medicine) were used to observe and evaluate the efficacy of local fluorosis symptoms and signs. The two drugs were observed for the overall effect, onset time, side effects, the patient’s tolerance to drugs. Results The effective rate of Fenbid group was 100% and that of Rongrong tablet group was 86.49% (P <0.005). Fenbid group onset time within 1W, side effects rate 20.00%; Cistanche tablets onset time in 7 ~ 15d, side effects rate 35.14%. Patients in both groups were better tolerated by drugs. Conclusion Fenbid is an effective drug for the treatment of local skeletal fluorosis, and its effect is obviously better than that of Rongrong tablet.